EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation

Jonathan L Metts iD, Matteo Trucco, Daniel A Weiser iD, Patrick Thompson, Eric Sandler, Tiffany Smith, Jessica Crimella, Samer Sansil iD, Ram Thapa, Brooke L Fridley, Nicholas Llosa, Thomas Badgett und 3 weitere

Cancer Medicine · 2023-02 · 12 (4) · 4270-4281

DOI: 10.1002/cam4.5297 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer Medicine, online erschienen am 23.09.2022. Verfasst von Jonathan L Metts und 14 weiteren Autor:innen. Beteiligte Einrichtung: Cancer and Blood Disorders Institute, Johns Hopkins All Children's Hospital, St Petersburg, Florida, USA. Hauptthemen laut MEDLINE: Sarcoma, Ewing, Metformin, Neoplasms, Central Nervous System Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Rally Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with relapsed and refractory solid and central nervous system (CNS) tumors have poor outcomes and need novel therapeutic options. Vincristine, irinotecan, and temozolomide (VIT) is a common chemotherapy regimen in relapsed pediatric tumors with an established toxicity profile. Metformin shows preclinical anti‐cancer activity through multiple pathways.

Methods

The objective of this Phase I trial was to establish the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) of metformin in combination with VIT in children with relapsed and refractory solid and CNS tumors. A 3 + 3 design was used to test the addition of metformin at five dose levels (666, 999, 1333, 1666, and 2000 mg/m 2 /day). Therapy toxicity, pharmacokinetics, and radiologic response to treatment were evaluated.

Results

Twenty‐six patients (median age 13 years, range 2–18 years) were enrolled with 22 evaluable for toxicity. The most common diagnoses were Ewing sarcoma ( n = 8), rhabdomyosarcoma ( n = 3) and atypical teratoid/rhabdoid tumor ( n = 3). The MTD was exceeded at Dose Level 5 due to two dose‐limiting toxicities; both were Grade 3 diarrhea requiring prolonged hospitalization and intravenous fluids. The MTD was not determined due to study closure with less than six patients enrolled at Dose Level 4. Frequently observed toxicities were gastrointestinal (most notably diarrhea) and hematologic. Amongst 16 patients evaluable for best overall response, there was one complete response (Ewing sarcoma), three partial responses (Ewing sarcoma, glioblastoma multiforme, and alveolar rhabdomyosarcoma), and five patients with stable disease.

Conclusions

The MTD of VIT with metformin was not determined due to premature study closure. We recommend an RP2D of Dose Level 4, 1666 mg/m 2 /day. Radiographic responses were seen in multiple tumor types. Further evaluation for efficacy could be investigated in a Phase II trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sarcoma, EwingMetforminNeoplasmsCentral Nervous System NeoplasmsChildHumansChild, PreschoolAdolescentIrinotecanTemozolomideVincristineCamptothecinDacarbazineMaximum Tolerated DoseAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, Local

Stichwörter der Autor:innen

irinotecanmetforminpediatricphase Itemozolomidevincristine

Substanzen

IrinotecanTemozolomideVincristineMetforminCamptothecinDacarbazine

Autor:innen und Institutionen

  • Cancer and Blood Disorders Institute, Johns Hopkins All Children's Hospital, St Petersburg, Florida, USA.
  • Cleveland Clinic Children's Hospital, Department of Pediatric Hematology-Oncology & Bone Marrow Transplantation, Cleveland, Ohio, USA.
  • Departments of Pediatrics and Genetics, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.
  • Division of Pediatric Hematology-Oncology, University of North Carolina Health Care, Chapel Hill, North Carolina, USA.
  • Department of Pediatric Oncology, Nemours Health Systems, Jacksonville, Florida, USA.
  • Cognitive Research Corporation, St Petersburg, Florida, USA.

ORCID-Profile: Jonathan L Metts, Daniel A Weiser, Samer Sansil, Damon Reed

Förderung

  • NCI NIH HHS
  • Rally Foundation

Zitieren

APA

Metts, J. L., Trucco, M., Weiser, D. A., Thompson, P., Sandler, E., Smith, T., Crimella, J., Sansil, S., Thapa, R., Fridley, B. L., Llosa, N., Badgett, T., Gorlick, R., Reed, D., & Gill, J. (2023). A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation. Cancer Medicine, 12(4), 4270-4281. https://doi.org/10.1002/cam4.5297

Vancouver

Metts JL, Trucco M, Weiser DA, Thompson P, Sandler E, Smith T, et al. A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation. Cancer Medicine. 2023;12(4):4270-4281. doi:10.1002/cam4.5297

BibTeX
@article{Metts2023,
  author = {Metts, Jonathan L and Trucco, Matteo and Weiser, Daniel A and Thompson, Patrick and Sandler, Eric and Smith, Tiffany and Crimella, Jessica and Sansil, Samer and Thapa, Ram and Fridley, Brooke L and Llosa, Nicholas and Badgett, Thomas and Gorlick, Richard and Reed, Damon and Gill, Jonathan},
  title = {A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation},
  journal = {Cancer Medicine},
  year = {2023},
  volume = {12},
  number = {4},
  pages = {4270--4281},
  doi = {10.1002/cam4.5297}
}
Kostenlos starten →